Abstract:Background: Although the diagnosis and treatment of glioblastoma (GBM) is significantly improved with recent progresses, there is still a large heterogeneity in therapeutic effects and overall survival. The aim of this study is to analyze gene expressions of transcription factors (TFs) in GBM so as to discover new tumor markers. Methods: Differentially expressed TFs are identified by data mining using public databases. The GBM transcriptome profile is downloaded from The Cancer Genome Atlas (TCGA). The nonnegative matrix factorization (NMF) method is used to cluster the differentially expressed genes to discover hub genes and signal pathways. The TFs affecting the prognosis of GBM are screened by univariate and multivariate COX regression analysis, and the receiver operating characteristic (ROC) curve is determined. The GBM hazard model and nomogram map are constructed by integrating the clinical data. Finally, the TFs involving potential signaling pathways in GBM are screened by Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Results: There are 68 differentially expressed TFs in GBM, of which 43 genes are upregulated and 25 genes are downregulated. NMF clustering analysis suggested that GBM patients are divided into three groups: Clusters A, B, and C. LHX2, MEOX2, SNAI2, and ZNF22 are identified from the above differential genes by univariate/multivariate regression analysis. The risk score of those four genes are calculated based on the beta coefficient of each gene, and we found that the predictive ability of the risk score gradually increased with the prolonged predicted termination time by time-dependent ROC curve analysis. The nomogram results have showed that the integration of risk score, age, gender, chemotherapy, radiotherapy, and 1p/19q can further improve predictive ability towards the survival of GBM. The pathways in cancer, phosphoinositide 3-kinases (PI3K)-Akt signaling, Hippo signaling, and proteoglycans, are highly enriched in high-risk groups by GSEA. These genes are mainly involved in cell migration, cell adhesion, epithelial-mesenchymal transition (EMT), cell cycle, and other signaling pathways by GO and KEGG analysis. Conclusion: The four-factor combined scoring model of LHX2, MEOX2, SNAI2, and ZNF22 can precisely predict the prognosis of patients with GBM.

Identification of a Specific Gene Module for Predicting Prognosis in Glioblastoma Patients

Identification of Glioblastoma Gene Prognosis Modules Based on Weighted Gene Co-Expression Network Analysis

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Identification of Key Immune and Cell Cycle Modules and Prognostic Genes for Glioma Patients through Transcriptome Analysis

Predicting Glioblastoma Prognosis Networks Using Weighted Gene Co-Expression Network Analysis on TCGA Data

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Identification of Survival‑associated Key Genes and Long Non‑coding RNAs in Glioblastoma Multiforme by Weighted Gene Co‑expression Network Analysis.

Development of an Immune-Related Prognostic Index Associated with Glioblastoma

Screening Seven Hub Genes Associated with Prognosis and Immune Infiltration in Glioblastoma.

Identification of candidate biomarkers for GBM based on WGCNA

A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients with GBM.

Identification of an Immune-Related Prognostic Signature for Glioblastoma by Comprehensive Bioinformatics and Experimental Analyses

Identification and validation of a novel robust glioblastoma prognosis model based on bioinformatics

Mining prognostic marker of glioma based on weighted gene co-expression network analysis

A Novel 16-Genes Signature Scoring System As Prognostic Model to Evaluate Survival Risk in Patients with Glioblastoma

Identification of Key Genes Involved in the Recurrence of Glioblastoma Multiforme Using Weighted Gene Co-Expression Network Analysis and Differential Expression Analysis.

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Identification and Validation of a 17-Gene Signature to Improve the Survival Prediction of Gliomas

Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas

A 5‐gene Prognostic Nomogram Predicting Survival Probability of Glioblastoma Patients

A Promising Glycolysis- and Immune-Related Prognostic Signature for Glioblastoma